Gout Treatment Linked to Reduced Risk of Heart Attack and Stroke, Major Study Finds
Treating gout to lower uric acid levels in the blood may significantly reduce the risk of life-threatening cardiovascular events like heart attacks and strokes, according to groundbreaking research published in JAMA Internal Medicine and reported by Medical Xpress. The findings offer a compelling new perspective on managing the inflammatory condition and its often-overlooked connection to heart health.
Gout, a common form of arthritis, affects an estimated one in 40 adults in the United Kingdom and the European Union. The condition arises when urate crystals accumulate in and around the joints, triggering sudden and intensely painful flare-ups. Beyond the immediate discomfort, gout has long been recognized as a risk factor for cardiovascular disease.
Researchers at the University of Nottingham sought to determine if aggressively lowering blood uric acid levels with medication could directly translate into improved cardiovascular outcomes. Previously, while achieving lower uric acid levels was known to reduce the frequency of gout attacks, the impact on heart attack and stroke risk remained largely unknown.
The study, conducted between January 2007 and March 2021, analyzed data from nearly 110,000 patients using the Aurum Clinical Practice Research Database, linked to hospital and mortality records. Participants, all age 18 or older, initially presented with serum uric acid levels exceeding 360 μmol/L (6 mg/dL). The team employed a “simulated experimental framework” – a method that leverages routinely collected healthcare data to accelerate research findings compared to traditional, lengthy clinical trials.
The analysis focused on identifying major adverse cardiovascular events – including heart attack, stroke, or death from cardiovascular disease – within five years of initiating uric acid-lowering medication. The results revealed a significant correlation between treatment and improved outcomes.
Patients in the group achieving target uric acid levels – specifically, those reaching below 360 μmol/L (6 mg/dL) – demonstrated a higher five-year survival rate and a demonstrably lower risk of serious cardiovascular events compared to those not reaching that target. Furthermore, the study highlighted a stronger association between achieving lower uric acid levels and reduced risk in patients already at high risk of cardiovascular disease.
Notably, patients who achieved even lower uric acid targets – below 300 μmol/L (5 mg/dL) – experienced an even greater reduction in both gout flare-ups and the risk of developing the condition. This suggests a dose-response relationship, where more aggressive uric acid control yields greater benefits.
These findings underscore the importance of proactive gout management, not just for alleviating joint pain, but for safeguarding long-term cardiovascular health. The research provides compelling evidence that treating gout effectively can be a crucial component of a comprehensive strategy to prevent heart attacks and strokes.
